Table 1 Proportion of HBV screening performed for each drugs
| Â | Total, n | Therapeutic Category (Alla), %) | All | HBsAg | HBsAb | HBcAb |
|---|---|---|---|---|---|---|
csDMARDs | 70,865 | Â | Â | Â | Â | Â |
 Methotrexate | 36,581 | MTX (10.6) | 3,893 (10.6) | 1,121 (30.6) | 4,736 (12.9) | 5,252 (14.4) |
 Salazosulfapyridine | 15,555 | Other csDMARDs (9.2) | 1,818 (11.7) | 5,537 (35.6) | 2,201 (14.1) | 2,489 (16.0) |
 Leflunomide | 187 | 5 (2.7) | 37 (19.8) | 9 (4.8) | 8 (4.3) | |
 Tacrolimus | 7,731 | 612 (7.9) | 2,111 (27.3) | 760 (9.8) | 792 (10.2) | |
 Sodium aurothiomalate | 98 | 3 (3.1) | 8 (8.2) | 3 (3.1) | 3 (3.1) | |
 Bucillamine | 5,957 | 277 (4.6) | 1,733 (29.1) | 373 (6.3) | 423 (7.1) | |
 Iguratimod | 4,542 | 419 (9.2) | 1,698 (37.4) | 516 (11.4) | 623 (13.7) | |
 Mizoribine | 214 | 9 (4.2) | 51 (23.8) | 11 (5.1) | 10 (4.7) | |
bDMARDs | 10,322 | Â | Â | Â | Â | Â |
 Abatacept | 1,802 | CTLA4-Ig (6.3) | 114 (6.3) | 321 (17.8) | 147 (8.2) | 177 (9.8) |
 Etanercept | 1,961 | TNF-α inhibitor (6.7) | 109 (5.6) | 348 (17.8) | 135 (6.9) | 148 (7.6) |
 Infliximab | 670 | 28 (4.2) | 70 (10.5) | 38 (5.7) | 36 (5.4) | |
 Adalimumab | 875 | 95 (10.9) | 180 (20.6) | 116 (13.3) | 119 (13.6) | |
 Certolizumab pegol | 358 | 23 (6.4) | 68 (19.0) | 34 (9.5) | 40 (11.2) | |
 Golimumab | 1,056 | 65 (6.2) | 187 (17.7) | 87 (8.2) | 105 (9.9) | |
 Tocilizumab | 3,418 | Anti-IL-6R therapy (10.3) | 334 (9.8) | 723 (21.2) | 381 (11.2) | 410 (12.0) |
 Sarilumab | 182 | 35 (19.2) | 66 (36.3) | 37 (20.3) | 41 (22.5) | |
tsDMARDs | 1,095 | Â | Â | Â | Â | Â |
 Tofacitinib citrate | 543 | Jak inhibitor (11.0) | 36 (6.6) | 102 (18.8) | 40 (7.4) | 49 (9.0) |
 Baricitinib | 463 | 73 (15.8) | 215 (46.4) | 80 (17.3) | 85 (18.4) | |
 Upadacitinib hydrate | 38 | 4 (10.5) | 16 (42.1) | 5 (13.2) | 5 (13.2) | |
 Filgotinib maleate | 10 | 1 (10.0) | 4 (40.0) | 2 (20.0) | 2 (20.0) | |
 Peficitinib hydrobromide | 41 | 6 (14.6) | 13 (31.7) | 6 (14.6) | 7 (17.1) |